Antimicrobial action and cell agglutination by the eosinophil cationic protein are modulated by the cell wall lipopolysaccharide structure

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2378-2385

  Pulido, David ^a   Moussaoui, Mohammed ^a   Andreu, David ^b   Nogués, M Victòria ^a   Torrent, Marc ^a,b   Boix, Ester ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; LIPOPOLYSACCHARIDE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; CELL AGGLUTINATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; INNATE IMMUNITY; PRIORITY JOURNAL; SEPSIS;

AGGLUTINATION; BACTERIAL ADHESION; BINDING SITES; CARBOHYDRATE CONFORMATION; CELL WALL; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILS; ESCHERICHIA COLI; HUMANS; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860198236     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06107-11     Document Type: Article

References (37)

1. Boix E, et al. 1999. Kinetic and product distribution analysis of human eosinophil cationic protein indicates a subsite arrangement that favors exonuclease-type activity. J. Biol. Chem. 274:15605-15614.
2. Boix E, Nogues MV. 2007. Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamily members involved in innate host defence. Mol. Biosyst. 3:317-335. (Pubitemid 46674863)
3. Boix E, Torrent M, Sanchez D, Nogues MV. 2008. The antipathogen activities of eosinophil cationic protein. Curr. Pharm. Biotechnol. 9:141-152. (Pubitemid 352024690)
4. Brandenburg K, Andra J, Garidel P, Gutsmann T. 2011. Peptide-based treatment of sepsis. Appl. Microbiol. Biotechnol. 90:799-808.
5. Brandenburg K, et al. 2010. Molecular basis for endotoxin neutralization by amphipathic peptides derived from the alpha-helical cationic coreregion of NK-lysin. Biophys. Chem. 150:80-87.
6. Brandenburg K, et al. 1993. Influence of the supramolecular structure of free lipid A on its biological activity. Eur. J. Biochem. 218:555-563. (Pubitemid 24003773)
7. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250. (Pubitemid 40298223)
8. Brown KL, Hancock RE. 2006. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18:24-30. (Pubitemid 43049644)
9. Caroff M, Karibian D. 2003. Structure of bacterial lipopolysaccharides. Carbohydr Res. 338:2431-2447. (Pubitemid 37509945)
10. Carreras E, Boix E, Rosenberg HF, Cuchillo CM, Nogues MV. 2003. Both aromatic and cationic residues contribute to the membrane-lytic and bactericidal activity of eosinophil cationic protein. Biochemistry 42:6636-6644. (Pubitemid 36666104)
11. Cohen J. 2002. The immunopathogenesis of sepsis. Nature 420:885-891. (Pubitemid 36019643)
12. Delcour AH. 2009. Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Acta 1794:808-816.
13. Ferguson AD, et al. 2001. Active transport of an antibiotic rifamycin derivative by the outer-membrane protein FhuA. Structure 9:707-716. (Pubitemid 32772893)
14. Fields GB, Noble RL. 1990. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept Protein Res. 35:161-214. (Pubitemid 20126875)
15. Frecer V, Ho B, Ding JL. 2004. De novo design of potent antimicrobial peptides. Antimicrob. Agents Chemother. 48:3349-3357. (Pubitemid 39129330)
16. García-Mayoral MF, et al. 2010. NMR structural determinants of eosinophil cationic protein binding to membrane and heparin mimetics. Biophys. J. 98:2702-2711.
17. Gutsmann T, et al. 2010. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob. Agents Chemother. 54:3817-3824.
18. Hancock RE. 1997. Peptide antibiotics. Lancet 349:418-422. (Pubitemid 27077684)
19. Hiruma R, Yamaguchi A, Sawai T. 1984. The effect of lipopolysaccharide on lipid bilayer permeability of beta-lactam antibiotics. FEBS Lett. 170:268-272. (Pubitemid 14119473)
20. Jeong H, et al. 2009. Genome sequences of Escherichia coli B strains REL606 and BL21(DE3). J. Mol. Biol. 394:644-652.
21. Laurents DV, et al. 2009. The (1)H, (13)C, (15)N resonance assignment, solution structure, and residue level stability of eosinophil cationic protein/RNase 3 determined by NMR spectroscopy. Biopolymers 91:1018-1028.
22. Mallorqui-Fernandez G, et al. 2000. Three-dimensional crystal structure of human eosinophil cationic protein (RNase 3) at 1.75 A resolution. J. Mol. Biol. 300:1297-1307.
23. Mangoni ML. 2011. Host-defense peptides: from biology to therapeutic strategies. Cell. Mol. Life Sci. 68:2157-2159.
24. Matsuzaki K, Sugishita K, Miyajima K. 1999. Interactions of an antimicrobial peptide, magainin 2, with lipopolysaccharide-containing liposomes as a model for outer membranes of gram-negative bacteria. FEBS Lett. 449:221-224. (Pubitemid 29192910)
25. Nikaido H. 2003. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67:593-656. (Pubitemid 37549772)
26. Prokhorenko IR, Zubova SV, Ivanov AY, Grachev SV. 2009. Interaction of Gram-negative bacteria with cationic proteins: dependence on the surface characteristics of the bacterial cell. Int. J. Gen. Med. 2:33-38.
27. Raetz CR. 1990. Biochemistry of endotoxins. Annu. Rev. Biochem. 59:129-170.
28. Sanchez D, et al. 2011. Mapping the eosinophil cationic protein antimicrobial activity by chemical and enzymatic cleavage. Biochimie 93:331-338.
29. Snyder DS, McIntosh TJ. 2000. The lipopolysaccharide barrier: correlation of antibiotic susceptibility with antibiotic permeability and fluorescent probe binding kinetics. Biochemistry 39:11777-11787.
30. Torrent M, et al. 2010. Comparison of human RNase 3 and RNase 7 bactericidal action at the Gram-negative and Gram-positive bacterial cell wall. FEBS J. 277:1713-1725.
31. Torrent M, et al. 2007. Topography studies on the membrane interaction mechanism of the eosinophil cationic protein. Biochemistry 46:720-733. (Pubitemid 46133588)
32. Torrent M, de la Torre BG, Nogues VM, Andreu D, Boix E. 2009. Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochem. J. 421:425-434.
33. Torrent M, Navarro S, Moussaoui M, Nogues MV, Boix E. 2008. Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 47:3544-3555. (Pubitemid 351399243)
34. Torrent M, Nogues MV, Boix E. 2011. Eosinophil cationic protein (ECP) can bind heparin and other glycosaminoglycans through its RNase active site. J. Mol. Recognit. 24:90-100.
35. Torrent M, et al. 2011. Refining the eosinophil cationic protein antibacterial pharmacophore by rational structure minimization. J. Med. Chem. 54:5237-5244.
36. Torrent M, et al. 2009. Comparison of the membrane interaction mechanism of two antimicrobial RNases: RNase 3/ECP and RNase 7. Biochim. Biophys. Acta 1788:1116-1125.
37. Venge P. 2010. The eosinophil and airway remodelling in asthma. Clin. Respir. J. 4(Suppl 1):15-19.